Sunny Pharmtech’s application for the addition of a new dosage form (sterile small-volume injectable) and the expansion of its sterile production line (automated sterile filling line on the 4th floor of Building 1) has undergone GMP inspection by the Ministry of Health and Welfare. The inspection results confirmed compliance with the PIC/S GMP guidelines for western medicinal products, and the manufacturing license has been granted.
Sunny Pharmtech Co., Ltd. (TWSE: 6676), announced today (16th) that it has signed exclusive licensing agreements with Company S for two of its developmental drugs, TMN-T for oncology and MSL-T for ulcerative colitis, targeting the U.S. market.
Anxo (6677) and Sunny Pharmtech (6676) have signed a cooperation agreement to jointly develop high-margin cardiovascular drugs aimed at challenging the patents of originator (Paragraph IV).
In the first half of 2024 (24H1), Sunny reported a revenue of 234 million NTD, setting a new record with a year-over-year (YoY) increase of 31.68%.
The demand for the multi-anticancer drug CPA-I is exceeding expectations. Sunny Pharmtech will initiate the optimization of the production line to double the capacity next year.
Sunny Pharmtech has signed a 5-year contract with a British pharmaceutical company for Carboprost injections, with plans to submit the application in 2024 Q4 and obtain UK drug approval in 2025 Q4.
Sunny Pharmtech has signed a contract with a British pharmaceutical company to collaborate in developing the Carboprost injection MENA market.
We use cookies to ensure that we give you the best experience on our website. More Info
